MEIP vs. TCRT, SLGL, SYBX, ONTX, BIVI, KALA, RNXT, FLGC, TXMD, and APM
Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Alaunos Therapeutics (TCRT), Sol-Gel Technologies (SLGL), Synlogic (SYBX), Onconova Therapeutics (ONTX), BioVie (BIVI), KALA BIO (KALA), RenovoRx (RNXT), Flora Growth (FLGC), TherapeuticsMD (TXMD), and Aptorum Group (APM). These companies are all part of the "pharmaceutical preparations" industry.
Alaunos Therapeutics (NASDAQ:TCRT) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
In the previous week, MEI Pharma had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for MEI Pharma and 0 mentions for Alaunos Therapeutics. MEI Pharma's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.
MEI Pharma has a consensus target price of $7.00, indicating a potential upside of 128.76%. Given Alaunos Therapeutics' higher probable upside, analysts plainly believe MEI Pharma is more favorable than Alaunos Therapeutics.
MEI Pharma has higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.
MEI Pharma has a net margin of 39.06% compared to MEI Pharma's net margin of 0.00%. Alaunos Therapeutics' return on equity of 39.72% beat MEI Pharma's return on equity.
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 6.2% of Alaunos Therapeutics shares are held by insiders. Comparatively, 3.9% of MEI Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
MEI Pharma received 367 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 60.62% of users gave MEI Pharma an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
Alaunos Therapeutics has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Summary
MEI Pharma beats Alaunos Therapeutics on 13 of the 14 factors compared between the two stocks.
Get MEI Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MEI Pharma Competitors List
Related Companies and Tools
